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poly-l-lactide microparticles as a controlled release delivery system
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Abstract: Vascular endothelial growth factor A (VEGF-A) is an important growth factor that plays a major role in angiogenesis. With
different isoforms distributed in various tissues, the shortest isoform of VEGF-A is VEGF121, one of the physiologically functional variants
next to VEGF165. It is well known that VEGF has a shorter half-life, and the stability of the protein must be considered in therapeutic
aspects. Poly-l-lactide (PLA) microparticles can release the encapsulated protein in a sustained release mode. In this study, the VEGF121
gene was cloned and expressed in a prokaryotic expression system (Escherichia coli). The recombinant VEGF121 was encapsulated
with PLA microparticles and studied in vitro and ex ovo for the sustained release mechanism. The PLA-VEGF microparticles and
the recombinant VEGF121 were explored for their bioactivity in human umbilical vein endothelial cells (HUVEC). VEGF released in
vitro from PLA microparticles on days 1, 20, and 30 showed remarkable biological activity compared to PBS-loaded PLA microparticles
such as the ability of the cells to proliferate, migrate, and form tubes similar to recombinant VEGF121. Besides, PLA-VEGF microparticles
and the recombinant VEGF121 were also tested for their proangiogenic action in embryonated eggs by chicken chorioallantoic membrane
assay (CAM), and the effect was observed in both forms. This study suggests that PLA-loaded VEGF microparticles in a sustainable
release format can be effectively used in proangiogenic therapy and reduce the adverse effects caused due to multiple dosages.
Key words: VEGF, purification, poly-l-lactide, human umbilical vein endothelial cells, proliferation, cell migration, CAM assay,
sustained release

1. Introduction
Angiogenesis is the formation of blood vessels from existing
vasculature in the body. This physiological process begins
from birth and continues throughout life in both healthy
and diseased individuals (Adair and Montani, 2010).
Vascular endothelial growth factor (VEGF) or vascular
permeability factor (VPF) (Senger et al., 1983; Ferrara
and Henzel, 1989) is an important protein helpful in the
formation of blood vessels, and it also plays an important
regulatory mechanism in physiological and pathological
process of angiogenesis (Folkman and Klagsbrun, 1987;
Nowak et al., 2010). VEGF is a heparin-binding growth
factor (Leung et al., 1989) and an effective mitogen for
endothelial cells (Walsh et al., 2002). VEGF-A, VEGF-B,
VEGF-C, VEGF-D, PGF (Placental Growth Factor),
and VEGF-E comprise proteins in the VEGF family
(Shibuya, 2011), which are present in human genomes
(Shibuya, 2011). These entire proteins share conserved
8 cysteine residues (Shibuya, 2011; Taktak-Ben Amar et
al., 2017), among which 2 cysteine residues contribute to

homodimer structure and the other six generate threeloop structures (Muller et al., 1997; Shibuya, 2011).
VEGF A binds to the receptors VEGFR-1 and VEGFR-2,
activates the angiogenesis pathways (Taktak-Ben Amar
et al., 2017), and helps in cell migration and vascular
permeability (Shibuya and Claesson-Welsh, 2006). VEGF
A has different splice variants such as VEGF121, VEGF165,
VEGF189, and VEGF206, depending upon the variations
in amino acids (Ferrara et al., 2003; Ferrara and Kerbel,
2005; Taktak-Ben Amar et al., 2017). In 1998, Huang et
al. found that endometrial stromal cells (the region where
angiogenesis takes place during the mid to late proliferative
phase) have an abundant expression of VEGF121 (Huang et
al., 1998). The molecular weight of VEGF121 (the isoform
used in this study) in homodimer form is 28 kDa and
16kDa in monomer form (Kim et al., 2007). VEGF121
signals through the VEGF receptor 2 (VEGFR2) and
is capable of increasing vessel diameter (Nakatsu et al.,
2003). During appropriate administration, VEGF can
promote angiogenesis and signal vascular endothelial cells
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which help in cell proliferation and migration (Geng et
al., 2011). Several clinical trials on proangiogenic growth
factor delivery have been successful (Makinen et al., 2002;
Rissanen et al., 2003; Adair and Montani, 2010; Rui et al.,
2012) while double-blinded clinical trials on intravenous
infusions of recombinant human VEGF failed to show
efficacy in a large group of patients. This could be due to
the instability or short half-life of the protein. (Simons et
al., 2002; Henry et al., 2003; Rui et al., 2012). Although
the therapeutic effects of this protein can be achieved at
high doses, it may lead to the development of vascular
tumors (Lee et al., 2000; Geng et al., 2011). Thus, it is
mandatory to provide a controlled delivery mechanism to
release the bioactive molecules directly to the desired site.
VEGF-loaded microparticles in a sustained release form
increased retinal vascular remodeling (Mezu-Ndubuisi
et al., 2019). PLA microparticle formulations available
in the market for clinical use include Lupron Depot and
Zoladex (endometriosis and prostate cancer applications),
Nutropin Depot (pediatric growth hormone deficiency),
and Bydureon (Type 2 diabetes) (Lee et al., 2016). Thus,
rVEGF will be efficient in combination with lactate (PLA),
which could be effectively used for tissue remodeling,
vasculogenesis, and angiogenesis.
In this study, we propose to explore the use of
poly-l-lactide (PLA) as a delivery system for VEGF121
and characterize the chemical properties of the PLA
microparticle. This system was investigated for surface
appearance and shape by scanning electron microscopy
(SEM) and drug release kinetics. Analysis of the
bioactivity of VEGF released from the PLA particle was
performed by testing in human umbilical vein endothelial
cells (HUVEC) for proliferation and wound healing assay.
Additionally, angiogenesis assay was performed in the
chicken chorioallantoic membrane (CAM). The ultimate
goal of this study is to identify the bioavailability and
stability of VEGF microspheres as potential candidates
for a localized delivery system for improving therapeutic
efficacy.
2. Materials and methods
2.1. VEGF121 construct preparation
The total RNA was extracted from Immortalized Human
Endometrial Stromal Cells (HESC) (ABM, Canada)
using an RNA easy kit (RNeasyMinikit, Qiagen Inc.,
Valencia, USA) as per the manufacturer’s procedure.
RT–PCR was performed for the first strand synthesis
using a Thermo Scientific Revert Aid First Strand cDNA
Synthesis Kit using random Hexa primers. The VEGF121
fragment was amplified from the cDNA clone by PCR
using Pfu DNA polymerase (MBI, Fermentas, MD,
USA) and VEGF121 gene-specific primers VGFF (NdeI):
5’CATATGGCACCCATGGCAGAAGGAGG3’ and VGFR

(BamHI): 5’GGATCCCCGCCTCGGCTTGTCACATC3’.
The amplification was carried out in a T100Tm Thermal
cycler (Bio-Rad) with initial denaturation at 94 °C for 3
min, followed by 30 cycles of denaturation at 94 °C for 45
s, annealing at 55 °C for 1 min, extension at 72 °C for 3 min
with a final extension of 72 °C for 10 min. The PCR products
were analyzed by electrophoresis in 1% low melting point
agarose gel with ethidium bromide. The amplicons were
purified using a GeneJET Gel extraction kit (ThermoFisher
Scientific, USA) and were cloned directionally into the
pET15b vector (Novagen, Madison, USA) at the Nde1 and
BamHI restriction sites. The recombinant clones selected
on Luria broth (LB) agar plates containing ampicillin (50
µg/mL) were verified by colony PCR, restriction enzyme
analysis and sequencing by universal T7 primers.
2.2. Expression and optimization of VEGF121 protein
The pETVEGF recombinant plasmid was transformed
into E. coli BL21 pLysS cells, and the individual colonies
were grown in LB medium at 37 °C until the culture
reached the midlog phase (OD600 nm of 0.4–0.5). The
expression was induced at 37 °C by using 1 mM isopropyl
β-D-1-thiogalactopyranoside (IPTG, Fermentas, USA) for
5 h. The temperature, IPTG concentration, solubility, and
the hour interval for the expression of foreign proteins in
E. coli BL21 pLysS were carried out as per the procedures
described by Jia et al. (Jia et al., 2007). Induced samples
were collected and analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) as per
standard procedures.
2.3. VEGF121 purification and refolding
An E. coli pellet expressing VEGF121 was suspended in 5
mL of solubilisation buffer (20 mM Tris HCl pH8.0, 500
mM NaCl, 8 M urea, 5mM βME, 0.5% Triton X-100, 1 mM
EDTA, 100 mM phenylmethylsulfonyl fluoride (PMSF),
and 0.5 mg/mL lysozyme) and sonicated for cell disruption
(Sonics Vibra-Cell VC 750 Sonicator) for 10 min at a burst
speed of 40% amplitude with a repetitive on/off cycle for
9 s. The sonicated samples were further centrifuged at
17,696 × g for 15 min. The insoluble recombinant VEGF
was purified using nickel affinity chromatography with
the binding of the N-terminal hexa-histidine tag. The
protein was bound to a column with repeated passing and
the column was washed with solubilization buffer with
20 mM imidazole. The recombinant VEGF121 (rVEGF121)
was eluted with 300 mM imidazole in the elution buffer
(solubilization buffer with imidazole). The eluted fractions
of protein were pooled and dialyzed in the dialysis buffer
(25 mM Tris HCl pH 8, 1 mm EDTA, 1 mM DTT, 5%
glycerol) containing between 8 M to 0 M urea, which was
routinely changed until precipitation occured and further
dialysis was carried out without urea to refold the protein
in a soluble form for its suitability in bioassays. The purified
proteins were assessed by SDS-PAGE and confirmed by
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Western blot and the concentration was estimated using
the Bicinchoninic acid (BCA) method (Boster Biological
Technology, CA, USA).
2.4. SDS-PAGE and western blot analysis
The production of rVEGF121 along with harvested and
eluted fractions were mixed separately with SDS sample
buffer and resolved by polyacrylamide gel electrophoresis
(PAGE) (12% resolving). The separated proteins done
by SDS-PAGE were transferred onto a Polyvinylidene
difluoride (PVDF) membrane (Bio-Rad) by Trans-Blot
Turbo Transfer System (Bio-Rad) at 25 volts for 7 min.
The membrane was blocked with 5% skim milk powder
in phosphate-buffered saline (PBS) overnight at 4 °C.
The rVEGF121 on the blot was detected by incubation
with Bevacizumab (Avastin, commercial anti-VEGF,
at a dilution of 1:10000) as primary antibody for 1 h at
room temperature. Then the blot was incubated with an
antihuman IgG HRP-conjugated (at a dilution of 1:10,000)
as a secondary antibody for 45 min. The peroxidase activity
was detected using the ChemiDoc Touch Imaging System
(Bio-Rad).
2.5. Preparation of VEGF-containing microparticles
Microparticles containing VEGF was prepared by double
emulsion solvent evaporation method (w/o/w) as described
by in the literature with slight modifications (Anugraha et
al., 2015; Rui et al., 2012). Briefly, 5 µg of rVEGF121 was
dissolved separately in 0.25 mL of 10% polyvinyl alcohol
(w/v) (PVA) (M.W. 30 to 70 kDa; 87%–90% hydrolyzed)
(Sigma-Aldrich, Bangalore, India) and 100 mg of
polylactide (M.W. 75–120 kDa (Sigma-Aldrich, Bangalore,
India) in 2 mL of dichloromethane (50 mg/mL) was
separately prepared. Both mixtures pooled together and
sonicated for 2 min at a burst speed of 40% amplitude with
a repetitive on/off cycle for 9 s. The emulsion was slowly
added into 75 mL of 5% PVA under vigorous agitation
in a magnetic stirrer. The microparticles formed through
overnight solvent evaporation were centrifuged (Thermo
scientific SORVALL LYNX 4000 centrifuge) at 10,000
× g/20 min/4 °C. The centrifugation was repeated twice
with sterile distilled water to remove any surfactants. The
pellet was lyophilized (Bench TopPro with Omnitronics Sp
Scientific) overnight to form a free-flowing powder. The
same way 200 µL of PBS was encapsulated with PLA to be
used as a control.
2.6. Characterization of VEGF microparticles
2.6.1. Estimation of encapsulation efficiency
The polymer was solubilized by accurately weighing 10
mg of the microparticles by dissolving it in acetonitrile.
The mixture was centrifuged at 10,000 × g/10 min at room
temperature (RT), the supernatant was discarded, and the
pellet was dried at 37 °C for an hour. Following this, 100
µL of PBS was added and centrifuged at 10,000 × g/10 min/
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RT. The supernatant was collected and the protein content
was estimated by BCA as per manufacturer’s protocol
(Boster Biological Technology, CA, USA). The absorbance
was read at 562 nm. The percentage of encapsulation
efficiency was calculated by the formula (µg of VEGF/mg
of PLA particles * 100).
2.6.2. Scanning electron microscopy (SEM)
The particles were prepared by double emulsion, and the
solvent evaporation method was subjected to scanning
electron microscopy (SEM) for analysis of size and
surface morphology (Carl ZEISS-EVO 18, Germany)
using tungsten filament at an operating voltage of 10
kV. Approximately 10 µg of the sample was coated with
gold atoms using a sputter coater (SC7620 ‘mini’ sputter
coater and glow discharge system, to enhance scattering
of electrons) with a vacuum pressure maintained at 1.32
× 10–5 mbar. The sample was loaded into the aluminum
holder stub using tweezers and double-sided carbon tape.
2.7. Release kinetics
In vitro release of VEGF from PLA was determined in
PBS at 37 °C. Briefly, 40 mg of the lyophilized powder
was redispersed in 1-mL PBS in a 1.5 mL microcentrifuge
tube, vortexed and centrifuged at 5422 × g/5 min, and the
supernatant was collected (0 h). Fresh 1 mL of PBS was
added, vortexed and placed in a 37 °C shaking incubator
at 80 rpm in a slanting position. The supernatant was
collected daily until day 30. After each collection, the
supernatant was replaced with fresh 1-mL PBS and
vortexed before being placed in 37 °C shaking incubator.
After collection, the supernatant was always divided into
2 parts: one for analyzing release efficiency and the other
for bioactivity assay. The same way PBS encapsulated with
PLA was also treated and collected in a 24-h fraction for
further experimental comparisons. All the supernatants
were stored at –80 °C until use.
2.8. SDS-PAGE analysis
The stability of the encapsulated microparticles was
analyzed in SDS-PAGE. A known amount of protein
VEGF121 encapsulated with PLA microparticles was
incubated with 0.1% of SDS-PBS (0.01 M; pH 7.4) RT
for 3 h by gentle shaking and then centrifuged at 20,584
× g for 25 min at 4 °C (Saini et al., 2011). The respective
supernatants were mixed with Laemmli buffer, heated at
95 °C, and analyzed in SDS-PAGE.
2.9. Microparticles release efficiency
The amount of VEGF encapsulated at each time point
was quantified by Enzyme Linked Immunosorbent Assay
(ELISA). Supernatant from all time points was prethawed
at 4 °C before use and measured by ELISA, according to
the manufacturer’s instructions (Human VEGF PicoKine
ELISA Kit, Boster Bio, CA, USA). Exactly 0.1 mL of the
supernatant from each time point (1 to 30 days) was added
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to the precoated 96-well plate. The plate was incubated at
37 °C for 90 min. The plate content was then discarded,
and 0.1 mL of the biotinylated antihuman VEGF antibody
was added to all of the wells and incubated at 37 °C for
60 min. The plates were washed thrice with wash buffer.
After washing the microtitre plate, 0.1 mL of AvidinBiotin-Peroxidase Complex was added into each well and
incubated at 37 °C for 30 min. Plates were washed 5 times
with washing buffer followed by addition of 90 µL of the
substrate into each well and incubated at 37 °C in the dark
for 20 min. Once the color started developing, 0.1 mL of
stop solution was added and the OD was determined at
450 nm within 30 min in a microplate reader (Spectramax
M5e, Molecular Devices).
2.10. Bioactivity of rVEGF121 and VEGF-loaded PLA microparticles
2.10.1. Proliferation and migration assay
Human umbilical vein endothelial cells (HUVEC) were
purchased from HiMedia Laboratories (Mumbai, India).
All experiments were performed using the cells below
passage 8. Cells were grown in HiEndoXLTM Endothelial
Cell Expansion Medium, Reduced Serum (HiMedia,
Mumbai, India). 5000 cells/well were cultivated in 96
well plates (Corning, NY, USA), in the specified medium
and were incubated in 5% CO2 incubator for the cells
to adhere to the wells. The medium was later replaced
with fresh serum and growth factor reduced medium
containing rVEGF121 (200 and 500 ng), 100 µL of VEGFloaded PLA microparticles (days 1, 20, and 30), and 100
µL of PBS-loaded PLA microparticles. Following this, its
effects on proliferation were determined, and 10 ng/mL
of commercially available recombinant VEGF121 (Sino
Biological, MD, USA) was used as a positive control. MTT
assay was performed as per the manufacturer’s protocol
(HiMedia, Mumbai, India), purple formazan was used
as an indicator, and the plate was spectrophotometrically
measured at 570 nm with an ELISA plate reader
(Spectramax M5e, Molecular Devices).
For migration assay, 5000 cells/well (Corning, NY,
USA) were seeded in 24-well plates and grown until a
monolayer was formed. The monolayer was scratched
with a sterile tip, the cellular debris was washed with
PBS, and the cells were thereafter incubated with and
without rVEGF121 (200 and 500 ng) for 12 h. Next, 100
µL of VEGF-loaded PLA microparticles (day 1, 20, and
30) and PBS-loaded PLA microparticles in serum-free
RPMI medium were incubated for 24 h. Cell images were
captured at a magnification of 4× in a camera connected
with an inverted microscope (Leica DMi1). Image J was
used to determine the wound healing percentage.
2.10.2. Endothelial tube formation assay
Approximately 96 well plates were coated with 50 µL/well
of precooled Matrigel (BD Biosciences) and incubated in

a humidified incubator (37 °C, 5% CO2) for 30 min for the
Matrigel to solidify. Then, 1 × 104 cells/well were seeded
with and without rVEGF121 (200 and 500 ng), 100µL of
VEGF-loaded PLA microparticles (day 1, 20, and 30),
and PBS-loaded PLA microparticles (negative control)
and incubated for 4 h. After the incubation, CalceinAM
(Trevigen), a fluorescent monitoring tube formation and
a cell-permeable dye were added at a final concentration
of 2 µg/mL and incubated for 30 min at 37 °C and
provided with 5% CO2 in a light-free environment. The
cell conditions and tube formation were monitored under
a Nikon Laser Scanning Confocal microscope model
C2 at 4× magnification, and the image was captured in
the camera provided with the microscope. The number
of tubes formed were analyzed using WimCam online
software (Wimasis, Onimagin Technologies SCA, Spain).
2.10.3. Chicken chorioallantoic membrane assay
Fresh embryonated eggs were purchased from the College
of Poultry Production and Management (CPPM) in
Hosur, India. The eggs were sterilized with 70% ethanol
and incubated at 37 °C at 60%–70% humidity. After 4 days,
the window of the embryonated chicken eggs was opened
by removing the shell membrane. Filter paper discs soaked
in PBS-PLA (negative control), rVEGF121 with 200 ng/
mL and 500 ng/mL or VEGF-loaded PLA particles (day
1, 20, and 30) with 10–100 ng/mL were applied to the
CAM individually, and the windows were sealed with
parafilm and incubated for 24 to 96 h. The live blood vessel
formation was recorded and photographed with a digital
camera at 10× magnification after 48 h. The response and
the total vessels network length of the blood vessels were
quantified with WimCAM online software (Wimasis,
Onimagin Technologies SCA, Spain)
2.11. Statistical analysis
The numerical data was represented as mean ± SD.
Statistical significance was analyzed using a Bonferroni
post-test using Graph Pad Prism, data analysis, and
graphical software. Probability (P) value was defined as
P < 0.05 and considered statistically significant, which is
indicated with asterisks.
3. Results
3.1. Amplification and cloning of isoform in pET 15b
vector
The VEGF121 gene sequence was amplified from HESC with
the gene-specific primers (Figure 1A). VEGF121 was excised,
purified and ligated into the pET15b vector at the NdeI and
BamHI sites. The E. coli DH5α cells were transformed with
the ligated mixture and the transformants were screened
by ampicillin selection. Presence of the gene-363 bp was
confirmed by PCR and restriction digestion with NdeI and
BamHI enzymes (data not shown). The ORF of the insert
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with N-terminal His tag was confirmed by sequencing
with T7 universal primers.
3.2. Heterologous protein expression and optimization
The positive clones were transformed into BL21 (DE3)
pLysS and analyzed in SDS-PAGE (Figure 1B). A single
intense thick band was observed at 16 kDa (Figure 1B, lane
3) corresponding to rVEGF121 whereas no proteins were
seen in the vector or uninduced controls (Figure 1B, lanes
1 and 2). The induction conditions were optimized by
postinduction temperature (25, 30, 35, and 37 °C). Various
inducer concentrations of IPTG (0, 0.5, 1, 1.5, and 2 mM)
and different period of induction times (0, 1, 2, 3, 4, 5, 6,
7, 8, 9, and 10 h) were compared with one another by the
simple analysis of expressed protein in SDS-PAGE (data
not shown). However, rVEGF121 was better expressed at 37
°C in E. coli BL21 (DE3) pLysS cells; subsequent expression
was seen up to 10 h of induction. The optimized duration
of 5 h induction with 1 mM IPTG concentration at 37 °C
incubation was chosen for further studies.
3.3. Purification, refolding, and characterization of
rVEGF121 protein
Rapid purification of the inclusion body fractions was
performed under denaturing conditions at RT using Histagged Ni-NTA resin (Qiagen, Germany). The unbound
proteins were washed and the His-tagged VEGF121 protein
was recovered by elution with 300 mM imidazole. Eluted
fractions containing the expected single rVEGF121 protein
were pooled and dialyzed for renaturation at 4 °C in
different urea concentrations from 8 M, 6 M, 4 M, 2 M,
1 M, and 0.5 M. The precipitation was observed in 0.5 M

urea and was further dialyzed without urea to bring the
refolded protein into a solubilized one. The protein was
confirmed by Western blot analysis (Figure 1C; (i) and (ii))
using Bevacizumab as a primary detection antibody.
3.4. Characterization of rVEGF121 loaded PLA microparticle
SEM analysis of PLA encapsulated rVEGF121 showed the
formation of a stable layer and spherical shape with smooth
surfaces (Figure 2A). This indicates that VEGF121 did not
form aggregation, and the size of the VEGF121 entrapped
PLA particles were from 11.2 ± 1.7 to 23.9 ± 3.08 µm. The
percentage encapsulation efficiency by BCA method of the
microparticle was found to be 75%.
3.5. In vitro drug release assay
The quantification of rVEGF121 was done by incubating
PLA microparticles in PBS at 37 °C for 30 days. ELISA
was used to estimate VEGF121 (Figure 2B) present in the
supernatant collected. Initially, there was a burst release
of microparticles, which could be due to the deposition of
protein on the surface of the microparticles. There were
sustained release rates observed from day 1 to day 30. The
cumulative release percentage at the end of the assay was
calculated as 30.5 ± 0.58%.
3.6. Stability of the protein
The purified rVEGF121 protein and the in vitro released
protein from PLA microparticles were run in SDSPAGE. The resolved bands of the released protein from
PLA particles revealed that microparticle preparation
conditions did not cause any degradation of the protein
(Figure 3), and the protein was found to be stable.

Figure 1. Cloning, expression, and western blotting analysis of VEGF 121: A. Agarose Gel Electrophoresis of the amplified VEGF
region from HESC: Lane 1 and 2: amplified VEGF 121 region; Lane 3: DNA ladder marker dye plus (TAKARA BIO INC.); B.
121
SDS- PAGE analysis expressed rVEGF 121: Lane 1: pET 15b vector control; Lane 2: pETVEGF, uninduced protein control; Lane M:
prestained protein ladder plus (Purogene, Genetix, New Delhi); Lane 3: pETVEGF, IPTG induced crude protein showing 16 kDa
thick band, which is absent in first two lanes; C. SDS-PAGE and western blot analysis for the purified rVEGF 121 protein: (i) SDS-PAGE
(ii); Western blot analysis; Lane M: prestained protein ladder plus (Purogene, Genetix, New Delhi); Lane 1: crude pETVEGF; Lane 4:
purified pETVEGF.

38

ABRAHAM et al. / Turk J Biol

Figure 2. Characterization of rVEGF121-loaded PLA microparticle: a) Scanning Electron Microscopy (SEM) image of rVEGF121
encapsulated by PLA microparticles (size, and morphology of the particles were analysed using image J); b) In vitro release of rVEGF121
entrapped from PLA microparticles. In vitro release of rVEGF121 from VEGF-PLA microparticles released at 24 h intervals were
determined.

Figure 3. SDS-PAGE profile of PLA encapsulated microparticles:
Lane 1: purified rVEGF121 (the arrow indicating 16 kDa);
Lane 2: rVEGF121 released in vitro from PLA encapsulated
microparticles (the arrow indicating 16 kDa); M: prestained
protein ladder plus (Page Ruler, Thermo Scientific).

3.7. In vitro proliferation assay
The proliferation of rVEGF121 and VEGF-PLA particles
were assessed in HUVEC cells. To evaluate the functionality
of the recombinant VEGF121, the cells were treated with
200 ng and 500 ng of rVEGF121 (Figure 4B) and positive
control. Recombinant VEGF121 and VEGF-PLA particles
significantly enhanced the HUVEC cells proliferation (P
< 0.0001). Cells treated with 500 ng and rVEGF121 showed
a significant proliferation of 43.51% compared to the cells
treated with 200 ng of rVEGF121 (35.04%). Meanwhile,
cells treated with VEGF121 microparticles collected at time
points (days 1, 20, and 30) showed significant proliferation
(P < 0.0001) at 41.36%, 17.76%, and 12.40%, respectively,

when compared with PBS-loaded PLA microparticles
(3.10%) (Figure 4B).
3.8. In vitro wound healing migration assay
Cells treated with recombinant VEGF121 and the rVEGF121loaded microparticles were employed in wound healing
assays. Recombinant VEGF121 facilitated significant
healing of the wound at 12 h (Figure 5A) compared to
the untreated control (100% in 500 ng of rVEGF121 and
92% in 200 ng rVEGF121) (Figure 5B). Even after 24 h,
the untreated cells were not able to heal the wounds
completely. Recombinant VEGF121 loaded microparticles
were also able to heal the wounds but at a slower rate. Day
1 had 95% (which is equivalent to the cells treated with
500 ng rVEGF121) while day 20 and 30 had 83% and 82%
migratory potential at 24 h. In contrast, the PBS-loaded
PLA microparticle showed a percentage of 75.82%, which
is similar or equal to the untreated control at 73.94%. Slow
healing was observed continuously until 96 h. (Figure
5C). This migration assay confirms that rVEGF121 and the
rVEGF121-loaded microparticles are biologically active.
However, rVEGF121 heals the wound faster and VEGF121loaded microparticles are slow and stable, confirming the
efficiency for prolonged healing.
3.9. Endothelial tube formation assay
HUVEC cells treated with rVEGF121 and rVEGF121loaded microparticles have the ability to form a tubelike structure. The number of endothelial tubes formed
was measured in cells treated with rVEGF121 (200 and
500 ng) and rVEGF121-loaded microparticles (day 1, 20,
and 30), which were compared with a PBS-loaded PLA
microparticle (negative control). The number of tubes
formed was significantly greater than the negative control
(Figure 6A). While the highest number of tubes observed
were in 500 ng (i.e. 113 ± 1.41, followed by 108 ± 2.82 for
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Figure 4A: In vitro proliferation assay in HUVEC cells: MTT proliferation assay of rVEGF121. HUVEC cells were incubated with various
concentrations of rVEGF121 for 24 h and compared to the effects with control (serum free RPMI). Absorbance read at 570 nm; the data
represented as mean ± S.D. from 3 replicates. The Y-axis shows the percentage of proliferation increase, normalized to control cells.
Asterisks (***) indicate significant differences of P < 0.0001 for 500 ng vs. 200 ng.

Figure 4B: In vitro proliferation assay in HUVEC cells. MTT proliferation response of PLA encapsulated rVEGF121. HUVEC cells incubated
with various concentrations for 24 h and compared with the negative control and positive control (500 ng of rVEGF121). Absorbance read
at 570 nm; the data represented as mean ± S.D. from 3 replicates. The Y-axis shows the percentage proliferation increase, normalized to
control cells. Asterisks (***) indicate significant differences of P < 0.0001 for PBS (negative control) vs. day 1, day 20, and day 30.
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Figure 5A. Effect of rVEGF121 and PLA–VEGF microparticles on HUVEC cells. Cell migration experiments were determined in wound
healing scratch experiments. Images of the gap area induced at 12 h: a) Untreated cells at 12 h; b) 200 ng of rVEGF121 at 12 h; c) 500
ng of rVEGF121 at 12 h; d) PLA–VEGF microparticles on day 1 at 24 h; e) PLA–VEGF microparticles on day 20 at 24 h; f) PLA–VEGF
microparticles on day 30 at 24 h.

Figure 5B. Effect of rVEGF121 microparticles on HUVEC cells. The histogram shows the percentage of cell-covered area for different
concentration of rVEGF121. Percentage effects were compared with the untreated control (UT). Data represented (mean ± S.D., n = 3) at
12h. Statistical significance shown is 200 ng and 500 ng vs. untreated group.

41

ABRAHAM et al. / Turk J Biol

Figure 5C. Effect of rVEGF121 loaded microparticles on HUVEC cells. Histogram
shows the percentage of cell-covered area at 24 h treated with rVEGF121-loaded
microparticles collected on different days. Data represented as mean ± S.D., n = 3.
Statistical significance compared with PBS-loaded PLA microparticle (negative
control).

200 ng concentration), day 1 samples of rVEGF121-loaded
microparticles formed 105 ± 1.41, followed by 51 ± 2.82
and 49 ± 1.41 for days 20 and 30, respectively (Figure 6B).
Analysis was done using Wimasis Image Analysis software
(Wimasis, 2016a).
3.10. Chicken chorioallantoic membrane assay
Recombinant VEGF121, rVEGF121-loaded microparticles
and PBS-loaded PLA microparticle (negative control)
were applied on third-day eggs for the evaluation of blood
vessels to check the proangiogenic action of VEGF. New
capillary blood vessels formed in all the groups after 48
h (Figure 7A). In the control groups (PBS-PLA), blood
vessel formation was normal whereas in eggs applied with
200 and 500 ng rVEGF121, there was a significant increase
in blood vessels; rVEGF121-loaded microparticles also
had a significant increase in the formation of blood vessel
network. (Figure 7B). Analysis was done with Wimasis
Image Analysis software (Wimasis, 2016b).
4. Discussion
Angiogenesis is the formation of new blood vessels
with many molecules involved in the process. It
occurs throughout life, and control of angiogenesis
(antiangiogenesis) can be used in cancer therapies (Adair
and Montani, 2010). Promotion (proangiogenesis) leads to
regeneration therapies like endometrium, diabetic wound
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healing, and cardiovascular diseases. VEGF, VEGF-A
with various isoforms expressed in many tissues, is one
of the important growth factors involved in physiological
angiogenesis, but an aberrant expression of VEGF leads to
pathological angiogenesis (Shibuya, 2011). Hence, VEGF
is often exploited in many clinical applications such as in
cancer therapeutics or diagnostics.
VEGF is very important in blood vessel formation in
the kidneys, brain, liver, and lungs. VEGF and angiogenesis
play an important role in endometrium regeneration
(Sharkey et al., 2000; Smith, 2001). When studied for
polymorphism, this gene has been linked to gynecologic
and obstetric conditions like recurrent implantation
failure (Jung et al., 2016). VEGF helps in endothelial
cell migration; in a study by Beckert et al., lactate
enhanced collagen synthesis influenced the production of
endothelial cells and thereby increased cellular migration
(Beckert et al., 2006). As discussed by Huang et al. VEGF121
was expressed in the endometrium as a 16 kDa protein in
recombinant form (Kazemi-Lomedasht et al., 2014) which
plays an important role in endometrium regeneration
(Huang et al. 1998) used as a source of gene for cloning
purpose.
We amplified the VEGF121 gene (363 bp), which was
composed of about 121 amino acids and ligated with a
bacterial expression vector (pET 15b) and sequenced
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Figure 6A. Effect of rVEGF121 and rVEGF121-loaded microparticles on tube formation. Images indicate the endothelial tube formation
after 4 h of incubation in HUVEC cells: a) PBS-PLA (negative control); b) 200 ng of rVEGF121; c) 500 ng of rVEGF121; d) PLA–VEGF
microparticles on day 1; e) PLA–VEGF microparticles on day 20; f) PLA–VEGF microparticles on day 30. Photographs were taken at a
20× magnification under a confocal microscope.

Figure 6B. Effect of rVEGF121 and PLA–VEGF microparticles on tube formation. Graphs show the number of endothelial tubes formed
by HUVEC cells exposed to PBS-PLA, different concentrations of rVEGF121 and PLA–VEGF microparticles collected at different days
for 4 h in Matrigel-coated 96 well plates. Data presented as mean ± S.D with n = 3. Asterisks (***) denote statistically significant
differences compared to PBS-loaded PLA microparticles (negative control).
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Figure 7A. Effect of rVEGF121 and PLA–VEGF microparticles on ex vivo angiogenesis. Filter discs soaked in a) PBS-PLA
(negative control); b) 200 ng of rVEGF121; c) 500 ng of rVEGF121; d) PLA–VEGF microparticles on day 1; e) PLA–VEGF
microparticles on day 20; f) PLA–VEGF microparticles on day 30. CAMs were photographed at a magnification of 10× with
digital camera after 48 h.

Figure 7B. Effect of rVEGF121 and PLA–VEGF microparticles on ex vivo angiogenesis:
graphical representation of the vessel length induced by different concentrations of
rVEGF121 and PLA–VEGF microparticles collected on different days. Quantitative
measurement of the total vessel network length was calculated; data is represented
as mean ± S.D., n = 3. Statistical significance was compared with PBS (PBS-PLA)
(negative control)
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after cloning in DH5α strain of E. coli. The E.coli system is
exploited for high-level expression and functionally active,
heterologous proteins (Kaur et al., 2018). There are several
recombinant proteins produced in the E.coli expression
system approved by the FDA for clinical use, including
Humulin (RH Insulin), IntronA (interferon α2b), Glucagon,
and Preos (parathyroid hormone) (Baeshen et al., 2015).
Producing the recombinant proteins in E.coli has several
advantages such as a shorter duration, faster growth, easy
maintenance, easy scale-up, inexpensive growth media,
and low cost (Rosano and Ceccarelli, 2014). The target of
this study is to successfully express VEGF121 in E.coli and
to check the bioactivity of rVEGF121, which could be used
as a proangiogenic drug for sustained release using PLA
polymer as a delivery system.
The slow delivery system of this protein will be
advantageous as VEGF121 has a shorter half-life of <90 min
(Rui et al., 2012); therefore, the carrier should be effective
in releasing VEGF in a controlled manner. PLA, approved
by the FDA, is safe, biodegradable, and has a long-standing
capacity (Simamora and Chern, 2006) and therefore used
extensively in medical applications.
Drug delivery systems can effectively work at the
target site and thus reduce the harmful effects caused
due to multiple dosages of drugs. PLA particles
encapsulated with VEGF have been successfully used
as nanosustained release microspheres, which induced
proliferation and differentiation of adipose-derived stem
cells (He et al., 2018). VEGF165 during encapsulation
with PLA microparticles stimulated vasculogenesis and
angiogenesis in an acute myocardial ischemia-reperfusion
rat model (Formiga et al. 2010). PLA encapsulation was
carried out with the double emulsion solvent evaporation
method (w/o/w) with the modifications from Rui at al.
(Rui et al., 2012; Anugraha et al., 2015). The size of the
PLA particles ranged from 11.2 to 23.9 µm. The amount
of polymer, nature of the solvent, preparation methods,
and stirring rate influences the size of the particle. As
reported by Howie et al. and Anugraha et al., larger size
particles have less effect and smaller size particles have
chances of more positivity (Howie et al., 1993; Anugraha
et al., 2015). Microspheres ranging from 10 to 200 µm
diameters achieved optimal release as reported by Han
et al (Han et al., 2016). The double emulsion method
requires high loading of the samples, which may also
result in protein degradation during the process of
sonication, centrifugation, and also interactions between
the protein and the polymer. This might have influenced
the interaction efficiency and is the possible reason for
having 75% encapsulation efficiency. The evaluation of the
microparticles from the resolved bands in the SDS-PAGE
proved that the protein is stable. Our results show a burst

release of VEGF during the preliminary days, and this
is because the encapsulated protein is distributed on the
surface and they were released instantly when engrossed
in PBS. ELISA and in vitro release kinetics provide an
overall idea of the study.
The bioactivity of rVEGF121 and the VEGF-PLA
microparticles were studied in HUVEC cells derived from
the endothelium of veins from the umbilical cord. They are
extensively used as a model in laboratories to characterize
the function of endothelial cells (Park et al., 2006). Wound
healing assays with different concentrations of rVEGF and
VEGF-PLA microparticles suggest that VEGF stimulates
angiogenesis and plays an important role in wound
healing and repair mechanisms. This also correlates with
the reported study by (Taktak-Ben Amar et al., 2017). The
wound-healing effect of VEGF-PLA microparticles were
slower when compared with rVEGF121 and the control,
but the day 1 released microparticles did not have any
significant difference when compared with the 500 ng of
rVEGF. However, all the particles were able to repair the
wounds, suggesting that the microparticles are stable and
bioactive whereas PBS-loaded PLA microparticles showed
similar results to that of the untreated control. The obtained
results also correlate with earlier findings (Bao et al., 2009;
Taktak-Ben Amar et al., 2017). HUVEC proliferation studies
also suggest that rVEGF121 and VEGF-PLA microparticles
are bioactive and have the ability to promote endothelial
cells in vitro. Wound healing is a multistep process that is
controlled by the involvement of different cells (Tonks et al.,
2003). While investigating the proliferation and migration
of rVEGF121 and rVEGF-encapsulated microparticles
in HUVEC cells, we found that rVEGF121 and rVEGFencapsulated microparticles accelerate wound closure more
quickly than the controls, indicating the stimulatory effect
of the recombinant protein and the encapsulated particles.
Biological activity was also characterized by endothelial
tube formation assay; all the samples were able to form
tubes when compared with the control. Tube formation
assay has numerous advantages as it is inexpensive, not
time-consuming, and quantifiable. This result correlates
with various reports already available for VEGF and also
has the reproducibility for VEGF and its loaded particles
proving to be bioactive. In vitro tube formation assay
possesses strong activities stimulating angiogenesis in vitro.
Recombinant VEGF121 and VEGF-PLA microparticles also
help in endothelial cell migration and promote angiogenesis
by forming new capillary blood vessels in the CAM model.
The total vessel length significantly increased in the eggs
when rVEGF121 and VEGF-PLA microparticles were used.
CAM assay provides a scientific understanding and the
capacity of the PLA microparticles on angiogenesis, cell
proliferation, and migration.

45

ABRAHAM et al. / Turk J Biol
To conclude, the study described here is a simple
approach for producing a successful, functionally
bioactive rVEGF121 in a bacterial expression system
and using it effectively for therapeutic applications
through a proper sustained delivery mode. The results
presented here are significant when compared with
the negative control (untreated or PBS-PLA) Thus, the
combined effects of PLA and rVEGF121 accelerate wound

healing in vitro, which could be used for wound closure
applications and as a proangiogenic drug on further in
vivo confirmation.
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